Search

Your search keyword '"Melisi, D"' showing total 356 results
Start Over Author "Melisi, D"
356 results on '"Melisi, D"'

4. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

Author

Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Di Marco, M.C., Rodriquenz, M.G., Centonze, F., Rapposelli, I.G., Giordano, G., De Vita, F., Stuppia, L., Avallone, A., Ratti, M., Paratore, C., Forti, L.G., Orsi, G., Valente, M.M., Gaule, M., Macchini, M., Carrera, P., Calzavara, S., Simbolo, M., Melisi, D., De Braud, F., Salvatore, L., De Lorenzo, S., Chiarazzo, C., Falconi, M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

7. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma

Author

Trestini, I, Paiella, S, Sandini, M, Sperduti, I, Elio, G, Pollini, T, Melisi, D, Auriemma, A, Solda, C, Bonaiuto, C, Tregnago, D, Avancini, A, Secchettin, E, Bonamini, D, Lanza, M, Pilotto, S, Malleo, G, Salvia, R, Bovo, C, Gianotti, L, Bassi, C, Milella, M, Trestini I., Paiella S., Sandini M., Sperduti I., Elio G., Pollini T., Melisi D., Auriemma A., Solda C., Bonaiuto C., Tregnago D., Avancini A., Secchettin E., Bonamini D., Lanza M., Pilotto S., Malleo G., Salvia R., Bovo C., Gianotti L., Bassi C., Milella M., Trestini, I, Paiella, S, Sandini, M, Sperduti, I, Elio, G, Pollini, T, Melisi, D, Auriemma, A, Solda, C, Bonaiuto, C, Tregnago, D, Avancini, A, Secchettin, E, Bonamini, D, Lanza, M, Pilotto, S, Malleo, G, Salvia, R, Bovo, C, Gianotti, L, Bassi, C, Milella, M, Trestini I., Paiella S., Sandini M., Sperduti I., Elio G., Pollini T., Melisi D., Auriemma A., Solda C., Bonaiuto C., Tregnago D., Avancini A., Secchettin E., Bonamini D., Lanza M., Pilotto S., Malleo G., Salvia R., Bovo C., Gianotti L., Bassi C., and Milella M.

Abstract

Background: Nutritional derangements are common hallmarks of pancreatic cancer (PC). Their early detection and management are usually overlooked in routine practice. This study aimed to explore preoperative nutritional status and its prognostic value in patients undergoing surgery for PC. Methods: Data from 73 patients who underwent surgery for PC from November 2015 to January 2018 at the General and Pancreatic Surgery Unit, The Pancreas Institute, University Hospital of Verona Hospital, Verona, Italy, were retrospectively evaluated. The Nutritional Risk Screening (NRS)-2002 was used to evaluate the preoperative nutritional risk. Body composition was assessed using bioimpedance vectorial analysis (BIVA) on the day prior to surgery. The effect of clinical, pathological, and nutritional characteristics on overall survival (OS) was investigated using a Cox and logistic regression model. Kaplan–Meier curves were compared using the log-rank test. Results: Most patients (80.8%) were at preoperative risk of malnutrition (NRS-2002 ≥ 3) despite a mean BMI of 24.1 kg/m2(± 4.3). Twenty-four patients (32.9%) received neoadjuvant therapy prior to surgery. Preoperative NRS-2002 was significantly higher in this subset of patients (p = 0.026), with a significant difference by chemotherapy regimens (in favor of FOLFIRINOX, p = 0.035). In a multivariate analysis, the only independent prognostic factor for OS was the NRS-2002 score (HR 5.24, p = 0.013). Particularly, the likelihood of 2-year survival was higher in NRS < 3 (p = 0.009). Conclusions: Our analysis confirms that preoperative malnutrition has a detrimental impact on OS in PC patients undergoing radical surgery for PC. Careful preoperative nutritional evaluation of PC patients should be mandatory, especially in those who are candidates for neoadjuvant therapy.

Published
2020

9. O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202

Author

Vogel, A., primary, Sahai, V., additional, Hollebecque, A., additional, Vaccaro, G., additional, Melisi, D., additional, Al-Rajabi, R., additional, Paulson, S., additional, Borad, M., additional, Gallinson, D., additional, Murphy, A., additional, Oh, D., additional, Dotan, E., additional, Catenacci, D., additional, Van Cutsem, E., additional, Lihou, C., additional, Zhen, H., additional, Veronese, L., additional, and Abou-Alfa, G., additional

Published
2022
Full Text
View/download PDF

11. Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrations

Author

Bonelli P, Tuccillo FM, Federico A, Napolitano M, Borrelli A, Melisi D, Rimoli MG, Palaia R, Arra C, and Carinci F

Subjects
Medicine (General), R5-920
Abstract

Patrizia Bonelli,1 Franca M Tuccillo,1 Antonella Federico,5 Maria Napolitano,2 Antonella Borrelli,1 Daniela Melisi,6 Maria G Rimoli,6 Raffaele Palaia,3 Claudio Arra,4 Francesco Carinci71Laboratory of Molecular Biology and Viral Oncogenesis; 2Department of Clinical Immunology; 3Department of Gastrointestinal-Hepatobiliary-Pancreatic Cancer Oncology Surgery; 4Animal Facility, National Cancer Institute G Pascale, Naples, Italy; 5Microtech Laboratory, Naples, Italy; 6Pharmaceutical and Toxicological Chemistry Department, School of Pharmacy, University "Federico II", Naples, Italy; 7Department of Maxillofacial Surgery, University of Ferrara, Ferrara, ItalyPurpose: Epidemiological, clinical, and laboratory studies have suggested that ibuprofen, a commonly used nonsteroidal anti-inflammatory drug, inhibits the promotion and proliferation of certain tumors. Recently, we demonstrated the antiproliferative effects of ibuprofen on the human gastric cancer cell line MKN-45. However, high doses of ibuprofen were required to elicit these antiproliferative effects in vitro. The present research compared the antiproliferative effects of ibuprofen delivered freely and released by poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) in MKN-45 cells.Methods: MKN-45 human gastric adenocarcinoma cells were treated with ibuprofen-loaded PLGA NPs. The proliferation of MKN-45 cells was then assessed by cell counting. The uptake of NPs was imaged by fluorescence microscopy and flow cytometry. The release of ibuprofen from ibuprofen-loaded PLGA NPs in the cells was evaluated by gas chromatography–mass spectrometry.Results: Dramatic inhibition of cellular proliferation was observed in cells treated with ibuprofen-loaded PLGA NPs versus those treated with free ibuprofen at the same concentration. The localization of NPs was cytoplasmic. The initiation of ibuprofen release was rapid, commencing within 2 hours, and then increased slowly over time, reaching a maximum concentration at 24 hours. The inhibition of proliferation was confirmed to be due to the intracellular release of ibuprofen from the NPs. Using PLGA NPs as carriers, ibuprofen exerted an antiproliferative activity at concentrations > 100 times less than free ibuprofen, suggesting greater efficiency and less cellular toxicity. In addition, when carried by PLGA NPs, ibuprofen more quickly induced the expression of transcripts involved in proliferation and invasiveness processes.Conclusion: Ibuprofen exerted an antiproliferative effect on MKN-45 cells at low concentrations. This effect was achieved using PLGA NPs as carriers of low doses of ibuprofen.Keywords: nonsteroidal anti-inflammatory drug (NSAID), proliferation, uptake, MKN-45 cells

Published
2012

14. SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Author

Abou-Alfa, G., primary, Sahai, V., additional, Hollebecque, A., additional, Vaccaro, G., additional, Melisi, D., additional, Al-Rajabi, R., additional, Paulson, A., additional, Borad, M., additional, Gallinson, D., additional, Murphy, A., additional, Oh, D., additional, Dotan, E., additional, Catenacci, D., additional, Van Cutsem, E., additional, Lihou, C., additional, Ren, H., additional, Bibeau, K., additional, Feliz, L., additional, and Vogel, A., additional

Published
2021
Full Text
View/download PDF

15. P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

Author

Bekaii-Saab, T., primary, Valle, J., additional, Van Cutsem, E., additional, Rimassa, L., additional, Furuse, J., additional, Ioka, T., additional, Macarulla, T., additional, Bridgewater, J., additional, Wasan, H., additional, Borad, M., additional, Vogel, A., additional, Lihou, C., additional, Zhen, H., additional, Jiang, P., additional, Langmuir, P., additional, and Melisi, D., additional

Published
2021
Full Text
View/download PDF

16. First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer

Author

Yap T, Vieito M, Baldini C, Sepulveda-Sanchez J, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier A, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem S, Man M, Gandhi L, Avsar E, and Melisi D

Abstract

PURPOSE: A novel, selective, next-generation transforming growth factor-beta receptor type 1 small molecule inhibitor, LY3200882, demonstrated promising preclinical data. This first-in-human trial evaluated safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of LY3200882 as monotherapy or with other anticancer agents in patients with advanced cancer. EXPERIMENTAL DESIGN: This phase I multicenter study of oral LY3200882 (NCT02937272) comprised dose escalation, monotherapy expansion in grade 4 glioma, and combination therapy in solid tumors (LY3200882 and PD-L1 inhibitor LY3300054), pancreatic cancer (PC; LY3200882, gemcitabine and nab-paclitaxel), and head and neck squamous cell cancer (LY3200882, cisplatin and radiation). RESULTS: Overall, 139 patients with advanced cancer were treated. Majority (93.5%) of patients experienced {greater than or equal to}1 treatment-emergent adverse events (TEAEs), with 39.6% LY3200882-related Grade 3 LY3200882-related toxicities were only observed in combination therapy arms. One patient in the PC arm experienced cardiovascular toxicity. The LY3200882 monotherapy RP2Ds were established in 2 schedules: 50 mg BID 2-weeks-on/2-weeks-off and 35 mg BID 3-weeks-on/1-week-off. Four patients with grade 4 glioma had durable RANO partial responses (PR) with LY3200882 monotherapy (n=3) or LY3200882-LY3300054 combination therapy (n=1). In treatment-naive patients with advanced PC, 6/12 patients achieved RECIST v1.1 PR and 3/12 patients demonstrated stable disease, for an overall 75% disease control rate with the combination of LY3200882, gemcitabine and nab-paclitaxel. CONCLUSIONS: LY3200882 as monotherapy and combination therapy was safe and well tolerated with preliminary antitumor activity observed in PC. Further studies to evaluate the efficacy of LY3200882 with gemcitabine and nab-paclitaxel in advanced PC are warranted.

Published
2021

18. 1619P Health-related quality of life with nalirifox versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial

Author

Melisi, D., Macarulla, T., de la Fouchardiere, C., Pazo Cid, R.A., Chandana, S., Dean, A., Kiss, I., Lee, W., Goetze, T.O., Van Cutsem, E., Paulson, A.S., Bekaii-Saab, T., Pant, S., Hubner, R., Xiao, Z., Zhang, L., Benzaghou, F.M., O'Reilly, E.M., and Wainberg, Z.A.

Published
2023
Full Text
View/download PDF

23. O-1 Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial

Author

Wainberg, Z., Melisi, D., Macarulla, T., Cid, R. Pazo, Chandana, S., Fouchardière, C. de la, Dean, A., Kiss, I., Lee, W., Goetze, T., Van Cutsem, E., Paulson, S., Bekaii-Saab, T., Pant, S., Hubner, R., Xiao, Z., Chen, H., Benzaghou, F., and O'Reilly, E.

Published
2023
Full Text
View/download PDF

25. Impact of pancreatic enzyme replacement therapy (PERT) on survival in patients affected by advanced pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy

Author

Trestini, I., primary, Carbognin, L., additional, Peretti, U., additional, Sperduti, I., additional, Caldart, A., additional, Melisi, D., additional, Auriemma, A., additional, Soldà, C., additional, Tregnago, D., additional, Avancini, A., additional, Pilotto, S., additional, Bria, E., additional, Tortora, G., additional, Reni, M., additional, and Milella, M., additional

Published
2020
Full Text
View/download PDF

26. Clinical impact of sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT)

Author

Trestini, I., primary, Paiella, S., additional, Sandini, M., additional, Hank, T., additional, Pollini, T., additional, Sperduti, I., additional, Melisi, D., additional, Auriemma, A., additional, Soldà, C., additional, Tregnago, D., additional, Avancini, A., additional, Lanza, M., additional, Malleo, G., additional, D'onofrio, M., additional, Gianotti, L., additional, Pilotto, S., additional, Salvia, R., additional, Del Castillo, C., additional, Bassi, C., additional, and Milella, M., additional

Published
2020
Full Text
View/download PDF

27. 1856P Clinical relevance of pancreatic enzyme replacement therapy (PERT) in patients affected by advanced pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy

Author

Peretti, U., primary, Trestini, I., additional, Carbognin, L., additional, Sperduti, I., additional, Caldart, A., additional, Melisi, D., additional, Auriemma, A., additional, Soldà, C., additional, Tregnago, D., additional, Avancini, A., additional, Pilotto, S., additional, Bria, E., additional, Tortora, G., additional, Reni, M., additional, and Milella, M., additional

Published
2020
Full Text
View/download PDF

28. 63P Multicentre match-paired analysis of advanced biliary cancer (ABC) long-term survivors: The BILONG study

Author

Caputo, F., primary, Gelsomino, F., additional, Spallanzani, A., additional, Pettorelli, E., additional, Benatti, S., additional, Ghidini, M., additional, Grizzi, G., additional, Ratti, M., additional, Merz, V., additional, Messina, C., additional, Tonelli, R., additional, Luppi, G., additional, Melisi, D., additional, Dominici, M., additional, and Salati, M., additional

Published
2020
Full Text
View/download PDF

29. 57P Third-line chemotherapy in advanced biliary cancers (ABC): Pattern of care, treatment outcome and prognostic factors from a multicenter study

Author

Rizzo, A., primary, Salati, M., additional, Merz, V., additional, Messina, C., additional, Ricci, A.D., additional, Palloni, A., additional, Frega, G., additional, De Lorenzo, S., additional, Caputo, F., additional, Gelsomino, F., additional, Spallanzani, A., additional, Mollica, V., additional, Abbati, F., additional, Carotenuto, P., additional, Pettorelli, E., additional, Benatti, S., additional, Luppi, G., additional, Melisi, D., additional, Dominici, M., additional, and Brandi, G., additional

Published
2020
Full Text
View/download PDF

30. 1560P Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Prevalence and clinical implications

Author

Trestini, I., primary, Paiella, S., additional, Sandini, M., additional, Hank, T., additional, Pollini, T., additional, Sperduti, I., additional, Melisi, D., additional, Auriemma, A., additional, Soldà, C., additional, Tregnago, D., additional, Avancini, A., additional, Malleo, G., additional, D'Onofrio, M., additional, Gianotti, L., additional, Pilotto, S., additional, Salvia, R., additional, del Castillo, C.F., additional, Bassi, C., additional, and Milella, M., additional

Published
2020
Full Text
View/download PDF

31. Chemotherapy and subsequent stereotactic body radiotherapy (SBRT) as a multimodal neoadjuvant approach for selected borderline resectable / locally advanced pancreatic adenocarcinoma

Author

Giuliani, T., primary, Di Gioia, A., additional, Micera, R., additional, Simoni, N., additional, Rossi, G., additional, Marchegiani, G., additional, Melisi, D., additional, Auriemma, A., additional, Bassi, C., additional, Milella, M., additional, Malleo, G., additional, Mazzarotto, R., additional, and Salvia, R., additional

Published
2020
Full Text
View/download PDF

37. Core curriculum. Oncologia clinica

Author

Antonelli, M, Zora, Baretta, Bianco, C, Bianco, R, Bria, E, Cancello, G, Ciardiello, F, Cingarlini, S, Condello, C, Damiano, V, Nullm, nullDe Laurentiis, Nullg, nullDella Vittoria Scarpati, Dieci, Mv, Forestieri, V, Nullg, nullDi Lorenzo, Nullm, nullDi Maio, Guarneri, V, Massari, F, Melisi, D, Morabito, A, Palmieri, G, Pensabene, M, Pepe, S, Perrone, F, Piccirillo, Mc, ARPINO, GRAZIA, CARLOMAGNO, Chiara, BIANCO, ANGELO RAFFAELE, CONTEGIACOMO, ALMA, LAURIA, ROSSELLA, MARINELLI, ALFREDO, MATANO, ELIDE, PERSICO, GIOVANNI, Antonelli M, Arpino G, Zora Baretta, Bianco C, Bianco R, Bria E, Cancello G, Carlomagno C, Bianco AR, Ciardiello F, Cingarlini S, Condello C, Contegiacomo A, Damiano V, De Laurentiis M, Della Vittoria Scarpati G, Dieci MV, Forestieri V, Di Lorenzo G, Di Maio M, Guarneri V, Lauria R, Marinelli A, Massari F, Matano E, Melisi D, Morabito A, Palmieri G, Pensabene M, Pepe S, Perrone F, Persico G, Piccirillo MC, Angelo Raffaele Bianco, Sabino De Placido, Giampaolo Tortora e Pierfranco Conte, Antonelli, M, Arpino, Grazia, Zora, Baretta, Bianco, C, Bianco, Roberto, Bria, E, Cancello, G, Carlomagno, Chiara, Bianco, ANGELO RAFFAELE, Ciardiello, F, Cingarlini, S, Condello, C, Contegiacomo, Alma, Damiano, V, Nullm, nullDe Laurentii, Nullg, nullDella Vittoria Scarpati, Dieci, Mv, Forestieri, Valeria, Nullg, nullDi Lorenzo, Nullm, nullDi Maio, Guarneri, V, Lauria, Rossella, Marinelli, Alfredo, Massari, F, Matano, Elide, Melisi, D, Morabito, A, Palmieri, G, Pensabene, M, Pepe, S, Perrone, F, Persico, Giovanni, Piccirillo, Mc, Lauria E, Bianco, R, and Forestieri, V

Published
2015

38. Proposta di PDTA per i pazienti affetti da tumore del pancreas

Author

Aliberti, C., Aprile, G., Bassi, C., NICOLO' BASSI, Benati, G., Bocus, P., Butturini, G., Capelli, P., Crinò, S., Robertis, R., D’onofrio, M., Matteo Fassan, Gabbrielli, A., Gregianin, M., Lonardi, S., Lora, O., Luchini, C., Malleo, G., Marinelli, V., Massani, M., Mazzarotto, R., Melisi, D., Morana, G., Nardi, M., CLAUDIO PASQUALI, Pastorelli, D., Scarpa, A., Simoni, N., Tinazzi Martini, P., Tortora, G., Zagonel, V., and Zamboni, G.

Published
2018

39. Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158)

Author

Fanotto, V., Uccello, M., Pecora, I., Rimassa, L., Leone, F., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Silvestris, N., Pietrantonio, F., Battaglin, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., Pellegrino, A., Ferrari, L., Bordonaro, R., Vivaldi, C., Gerratana, L., Bozzarelli, S., Filippi, R., Bilancia, D., Russano, M., and Aprile, G.

Published
2018

40. The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC)

Author

Paiella, S., primary, Trestini, I., additional, Sperduti, I., additional, Sandini, M., additional, Elio, G., additional, Melisi, D., additional, Auriemma, A., additional, Soldà, C., additional, Tregnago, D., additional, Avancini, A., additional, Secchettin, E., additional, Bonamini, D., additional, Malleo, G., additional, Gianotti, L., additional, Pilotto, S., additional, Bassi, C., additional, and Milella, M., additional

Published
2019
Full Text
View/download PDF

41. Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer

Author

Ciardiello, D., primary, Belli, V., additional, Cardone, C., additional, Vitiello, P.P., additional, Martini, G., additional, Poliero, L., additional, Borrelli, C., additional, Arrichiello, G., additional, Ciaramella, V., additional, Matrone, N., additional, Barra, G., additional, De Falco, V., additional, Giunta, E.F., additional, Morgillo, F., additional, Troiani, T., additional, Terminiello, M., additional, Melisi, D., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2019
Full Text
View/download PDF

42. FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

Author

Vogel, A., primary, Sahai, V., additional, Hollebecque, A., additional, Vaccaro, G., additional, Melisi, D., additional, Al-Rajabi, R., additional, Paulson, A.S., additional, Borad, M.J., additional, Gallinson, D., additional, Murphy, A.G., additional, Oh, D.-Y., additional, Dotan, E., additional, Catenacci, D.V., additional, Van Cutsem, E., additional, Lihou, C.F., additional, Zhen, H., additional, Féliz, L., additional, and Abou-Alfa, G.K., additional

Published
2019
Full Text
View/download PDF

43. Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients

Author

Merz, V., primary, Zecchetto, C., additional, Santoro, R., additional, Simionato, F., additional, Piro, G., additional, Sabbadini, F., additional, Cavaliere, A., additional, Casalino, S., additional, Auriemma, A., additional, and Melisi, D., additional

Published
2019
Full Text
View/download PDF

45. A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer

Author

Humphries, MP, Rajan, SS, Droop, A, Suleman, CAB, Carbone, C, Nilsson, C, Honarpisheh, H, Cserni, G, Dent, J, Fulford, L, Jordan, LB, Jones, JL, Kanthan, R, Litwiniuk, M, Di Benedetto, A, Mottolese, M, Provenzano, E, Shousha, S, Stephens, M, Walker, RA, Kulka, J, Ellis, IO, Jeffery, M, Thygesen, HH, Cappelletti, V, Daidone, MG, Hedenfalk, IA, Fjällskog, M-L, Melisi, D, Stead, LF, Shaaban, AM, and Speirs, V

Abstract

Purpose: Breast cancer (BC) affects both genders, but is understudied in men. Although still rare, male BC is being diagnosed more frequently. Treatments are wholly informed by clinical studies conducted in women, based on assumptions that underlying biology is similar. Experimental design: A transcriptomic investigation of male and female BC was performed, confirming transcriptomic data in silico. Biomarkers were immunohistochemically assessed in 697 MBCs (n=477, training; n=220, validation set) and quantified in pre- and post-treatment samples from a male BC patient receiving Everolimus and PI3K/mTOR inhibitor. Results: Gender-specific gene expression patterns were identified. eIF transcripts were up-regulated in MBC. eIF4E and eIF5 were negatively prognostic for overall survival alone (Log rank; p=0.013; HR=1.77, 1.12-2.8 and p=0.035; HR=1.68, 1.03-2.74, respectively), or when co-expressed (p=0.01; HR=2.66, 1.26-5.63), confirmed in the validation set. This remained upon multivariate Cox regression analysis (eIF4E p=0.016; HR 2.38 (1.18-4.8), eIF5 p=0.022; HR 2.55 (1.14-5.7); co-expression p=0.001; HR=7.04 (2.22-22.26)). Marked reduction in eIF4E and eIF5 expression was seen post BEZ235/Everolimus, with extended survival. Conclusions: Translational initiation pathway inhibition could be of clinical utility in male BC patients overexpressing eIF4E and eIF5. With mTOR inhibitors which target this pathway now in the clinic, these biomarkers may represent new targets for therapeutic intervention, although further independent validation is required.

Published
2017

47. Functional inhibition of TGF-β in colorectal cancer cells and its interaction with AXL receptor

Author

Ciardiello, D., primary, Martini, G., additional, Matrone, N., additional, Belli, V., additional, Vitiello, P.P., additional, Cardone, C., additional, Ciaramella, V., additional, Barra, G., additional, Poliero, L., additional, Borrelli, C., additional, Troiani, T., additional, Melisi, D., additional, Morgillo, F., additional, Giunta, E.F., additional, De Falco, V., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2018
Full Text
View/download PDF

48. First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe

Author

Taieb, J., primary, Carrato, A., additional, Westphalen, B., additional, Melisi, D., additional, Prager, G., additional, Macarulla Mercade, T., additional, Mellbring, ÅB.C., additional, d'Esquermes, N., additional, Ferreras, A., additional, and de Jong, F., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results